Ubs Group Ag Omeros Corp Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Omeros Corp stock. As of the latest transaction made, Ubs Group Ag holds 450,074 shares of OMER stock, worth $4.45 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

450,074

Previous 482,135 6.65%

Holding current value

$4.45 Million

Previous $1.96 Million 8.74%

% of portfolio

0.0%

Previous 0.0%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$3.54 - $5.47 $113,495 - $175,373	-32,061 Reduced 6.65%	450,074 $1.79 Million
Q2 2024 Aug 13, 2024	SELL	$3.04 - $4.23 $171,902 - $239,193	-56,547 Reduced 10.5%	482,135 $1.96 Million
Q1 2024 May 13, 2024	BUY	$2.88 - $4.89 $127,111 - $215,825	44,136 Added 8.92%	538,682 $1.86 Million
Q4 2023 Feb 09, 2024	SELL	$1.08 - $3.63 $103,783 - $348,828	-96,096 Reduced 16.27%	494,546 $1.62 Million
Q3 2023 Nov 09, 2023	BUY	$2.81 - $5.69 $25,767 - $52,177	9,170 Added 1.58%	590,642 $1.72 Million
Q2 2023 Aug 11, 2023	BUY	$4.45 - $7.57 $260,765 - $443,594	58,599 Added 11.21%	581,472 $3.16 Million
Q1 2023 May 12, 2023	SELL	$2.48 - $5.22 $324,341 - $682,687	-130,783 Reduced 20.01%	522,873 $2.43 Million
Q4 2022 Feb 08, 2023	BUY	$1.75 - $3.96 $1,597 - $3,615	913 Added 0.14%	653,656 $1.48 Million
Q3 2022 Nov 10, 2022	SELL	$3.09 - $7.46 $68,094 - $164,396	-22,037 Reduced 3.27%	652,743 $2.06 Million
Q2 2022 Aug 10, 2022	BUY	$1.92 - $6.28 $250,099 - $818,032	130,260 Added 23.92%	674,780 $1.86 Million
Q1 2022 May 16, 2022	BUY	$5.07 - $7.2 $3,817 - $5,421	753 Added 0.14%	544,520 $3.27 Million
Q4 2021 Feb 14, 2022	BUY	$5.67 - $8.54 $113,139 - $170,407	19,954 Added 3.81%	543,767 $3.5 Million
Q3 2021 Nov 15, 2021	BUY	$13.4 - $16.3 $482,091 - $586,425	35,977 Added 7.37%	523,813 $7.22 Million
Q2 2021 Aug 13, 2021	BUY	$14.81 - $19.13 $121,634 - $157,114	8,213 Added 1.71%	487,836 $7.24 Million
Q1 2021 May 12, 2021	SELL	$14.52 - $23.53 $2.05 Million - $3.32 Million	-140,907 Reduced 22.71%	479,623 $8.54 Million
Q4 2020 Feb 11, 2021	BUY	$10.14 - $15.19 $856,890 - $1.28 Million	84,506 Added 15.77%	620,530 $8.86 Million
Q3 2020 Nov 12, 2020	BUY	$9.57 - $21.32 $506,607 - $1.13 Million	52,937 Added 10.96%	536,024 $5.42 Million
Q2 2020 Jul 31, 2020	SELL	$12.21 - $16.99 $245,579 - $341,719	-20,113 Reduced 4.0%	483,087 $7.11 Million
Q1 2020 May 01, 2020	SELL	$9.03 - $19.72 $8,867 - $19,365	-982 Reduced 0.19%	503,200 $6.73 Million
Q4 2019 Feb 14, 2020	BUY	$13.01 - $17.15 $791,294 - $1.04 Million	60,822 Added 13.72%	504,182 $7.1 Million
Q3 2019 Nov 14, 2019	BUY	$14.55 - $20.56 $633,507 - $895,182	43,540 Added 10.89%	443,360 $7.24 Million
Q2 2019 Aug 14, 2019	SELL	$15.0 - $19.62 $53,865 - $70,455	-3,591 Reduced 0.89%	399,820 $6.27 Million
Q1 2019 May 14, 2019	BUY	$11.65 - $17.72 $20,597 - $31,328	1,768 Added 0.44%	403,411 $7.01 Million
Q4 2018 Feb 14, 2019	BUY	$10.72 - $16.73 $203,755 - $317,987	19,007 Added 4.97%	401,643 $4.48 Million
Q3 2018 Nov 14, 2018	SELL	$17.73 - $26.69 $138,471 - $208,448	-7,810 Reduced 2.0%	382,636 $9.34 Million
Q2 2018 Aug 14, 2018	SELL	$10.79 - $24.44 $77,008 - $174,428	-7,137 Reduced 1.8%	390,446 $7.08 Million
Q1 2018 May 15, 2018	BUY	$9.0 - $20.16 $308,610 - $691,286	34,290 Added 9.44%	397,583 $4.44 Million
Q4 2017 Feb 14, 2018	BUY	$13.26 - $22.86 $36,876 - $63,573	2,781 Added 0.77%	363,293 $7.06 Million
Q3 2017 Nov 14, 2017	SELL	$19.76 - $24.9 $788,878 - $994,082	-39,923 Reduced 9.97%	360,512 $7.79 Million
Q2 2017 Aug 14, 2017	BUY	N/A	2,079 Added 0.52%	400,435 $7.97 Million
Q1 2017 Nov 14, 2017	BUY	N/A	398,356	398,356 $6.02 Million

Others Institutions Holding OMER

# of Institutions

121

Shares Held

25.6M

Call Options Held

228K

Put Options Held

630K

View Full List

About OMEROS CORP

Ticker OMER
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,730,000
Market Cap $620M
Description
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical program...

More about OMER

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account